Self-assembling peptide-based nanoparticles enhance anticancer effect of ellipticine in vitro and in vivo

References

• LiQTainskyMAEpigenetic silencing of IRF7 and/or IRF5 in lung cancer cells leads to increased sensitivity to oncolytic virusesPLoS One20116e2868322194884
   PubMed Web of Science ®Google Scholar
• ZhangWChenYWeiHAntiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenograftsClin Cancer Res2008146432643918927282
   PubMed Web of Science ®Google Scholar
• DaraseliaNWangYBudoffAMolecular signature and pathway analysis of human primary squamous and adenocarcinoma lung cancersAm J Cancer Res201229310322206048
   PubMed Web of Science ®Google Scholar
• GongHCWangSMayerGSignatures of drug sensitivity in nonsmall cell lung cancerInt J Proteomics872011 [Epub ahead of print.]
   Google Scholar
• DrobnienėMCicėnienėAZelvienėTPTargeted therapy in patients with non-small cell lung cancer previously treated with chemotherapyMedicina (Kaunas)20114752052522156604
   PubMed Web of Science ®Google Scholar
• BykadiGFloraKPCradockJCPoochikianGKDetermination of ellipticine in biological samples by high-performance liquid chromatographyJ Chromatogr19822311371447119056
   PubMed Web of Science ®Google Scholar
• AuclairCMultimodal action of antitumor agents on DNA: the ellipticine seriesArch Biochem Biophys19872591143318697
   PubMed Web of Science ®Google Scholar
• StiborováMBielerCAWiesslerMFreiEThe anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adductsBiochem Pharmacol2001621675168411755121
   PubMed Web of Science ®Google Scholar
• SinghMPHillGCPéoc’hDRaynerBImbachJLLownJWHigh-field NMR and restrained molecular modeling studies on a DNA heteroduplex containing a modified apurinic abasic site in the form of covalently linked 9-aminoellipticineBiochemistry19943310271102858068666
   PubMed Web of Science ®Google Scholar
• MonnotMMauffretOSimonVDNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivativesJ Biol Chem1991266182018291846365
   PubMed Web of Science ®Google Scholar
• FosséPRenéBCharraMPaolettiCSaucierJMStimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationshipMol Pharmacol1992425905951331751
   PubMed Web of Science ®Google Scholar
• Froelich-AmmonSJPatchanMWOsheroffNThompsonRBTopoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopyJ Biol Chem199527014998150047797481
   PubMed Web of Science ®Google Scholar
• StiborováMArltVMHendersonCJRole of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH: cytochrome P450 reductase null mouseToxicol Appl Pharmacol2008226258327
   Web of Science ®Google Scholar
• PoljakováJDračínskýMFreiEHudečekJStiborováMThe effect of PH on peroxidase-mediated oxidation of and DNA adduct formation by ellipticineCollect Czechoslov Chem Commun20097111691185
   Google Scholar
• GarbettNCGravesDEExtending nature’s leads: the anticancer agent ellipticineCurr Med Chem Anticancer Agents2004414917215032720
   PubMedGoogle Scholar
• ClarysseABrugarolasASiegenthalerPPhase II study of 9-hydroxy-2 N-methylellipticinium acetateEur J Cancer Clin Oncol1984202432476538489
   PubMedGoogle Scholar
• WangYLiYWangQWuJFangXPharmacokinetics and biodistribution of paclitaxel-loaded pluronic P105/L101 mixed polymeric micellesYakugaku Zasshi200812894195018520140
   PubMed Web of Science ®Google Scholar
• PortneyNGOzkanMNano-oncology: drug delivery, imaging, and sensingAnal Bioanal Chem200638462063016440195
   PubMed Web of Science ®Google Scholar
• GreenMRManikhasGMOrlovSAbraxane, a novel cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancerAnn Oncol2006171263126816740598
   PubMed Web of Science ®Google Scholar
• CorbinIRZhengGMimicking nature’s nanocarrier: synthetic low-density lipoprotein-like nanoparticles for cancer-drug deliveryNanomedicine (Lond)2007237538017716181
   PubMedGoogle Scholar
• FungSYYangHChenPSequence effect of self-assembling peptides on the complexation and in vitro delivery of the hydrophobic anticancer drug ellipticinePLoS One200834e195618398476
   PubMed Web of Science ®Google Scholar
• LawMJafariMChenPPhysicochemical characterization of siRNA-peptide complexesBiotechnol Prog20082495796319194904
   PubMed Web of Science ®Google Scholar
• KimSWKimNYChoiYBParkSHYangJMShinSRNA interference in vitro and in vivo using an arginine peptide/siRNA complex systemJ Control Release201014333534320079391
   PubMed Web of Science ®Google Scholar
• ZhangSHolmesTLockshinCRichASpontaneous assembly of a self-complementary oligopeptide to form a stable macroscopic membraneProc Natl Acad Sci U S A199390333433387682699
   PubMed Web of Science ®Google Scholar
• FungSYOyaizuTYangHThe potential of nanoscale combinations of self-assembling peptides and amino acids of the src tyrosine kinase inhibitor in acute lung injury therapyBiomaterials2011324000400821376387
   PubMed Web of Science ®Google Scholar
• ZhangSHolmesTCDiPersioCMHynesROSuXRichASelf- complementary oligopeptide matrices support mammalian cell attachmentBiomaterials199516138513938590765
   PubMed Web of Science ®Google Scholar
• FungSYYangHBholaPTSelf-assembling peptide as a potential as a potential carrier for hydrophobic anticancer drug ellipticine: complexation, release and in vitro deliveryAdv Funct Mater2009197483
   Web of Science ®Google Scholar
• BawaRFungSYShiozakiASelf-assembling peptide-based nanoparticles enhance cellular delivery of the hydrophobic anticancer drug ellipticine through caveolae-dependent endocytosisNanomedicine912011 [Epub ahead of print.]
   Web of Science ®Google Scholar
• ZhangSEmerging biological materials through molecular self-assemblyBiotechnol Adv20022032133914550019
   PubMed Web of Science ®Google Scholar
• GarbettNCGravesDEExtending nature’s leads: the anticancer agent ellipticineCurr Med Chem Anticancer Agents2004414917215032720
   PubMedGoogle Scholar
• SaijoNTamuraTNishioKStrategy for the development of novel anticancer drugsCancer Chemother Pharmacol200352Suppl 1S9710112856152
   PubMed Web of Science ®Google Scholar